| ²é¿´: 299 | »Ø¸´: 0 | |||
СÀÁÓãÓãͳæ (СÓÐÃûÆø)
|
[ÇóÖú]
thomsonÒ©Îﱨ¸æSWOTÀïµÄÄÚÈÝ
|
|
Superior viral suppression compared with Atripla (88% vs 81%), driven by improved tolerability translating to fewer dropouts in the dolutegravir-containing arm, according to the SINGLE study |
» ²ÂÄãϲ»¶
291Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ҩѧר˶µ÷¼Á
ÒѾÓÐ10È˻ظ´
Ò»Ö¾Ô¸211£¬0703»¯Ñ§305·ÖÇóµ÷¼Á
ÒѾÓÐ32È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
211±¾¿Æ²ÄÁÏ»¯¹¤Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ23È˻ظ´
085410 273Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
291·Öµ÷¼Á
ÒѾÓÐ6È˻ظ´
310Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
ҩѧ305Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´














»Ø¸´´ËÂ¥